Login to Your Account



Ariad wins accelerated approval for second-line NSCLC drug brigatinib

By Michael Fitzhugh
Staff Writer

Monday, May 1, 2017

Takeda Pharmaceutical Co. Ltd. subsidiary Ariad Pharmaceuticals Inc. won accelerated approval from the FDA for Alunbrig (brigatinib).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription